Journal of Health Economics

TytoCare Announces $49 Million Funding Round and Launches New Care Modules

Retrieved on: 
Thursday, August 3, 2023
Journal of Health Economics, Asthma, Tel Aviv University, Health care, Stanford University, Ohr Torah Stone, Health maintenance organization, Tyto, Journal, Patient, Growth, Entrepreneurship, AI, ROI, FDA, Insight Partners, Nursing

This new investment brings the company’s total funding to $205 million to date.

Key Points: 
  • This new investment brings the company’s total funding to $205 million to date.
  • The round was led by global software investor Insight Partners, which also led TytoCare’s previous round.
  • As TytoCare continues to grow, we hope to help more people experience clinic-quality care from home, and help unlock the potential of remote care,” said Dedi Gilad, Co-Founder and CEO of TytoCare.
  • In particular, TytoCare will advance the Home Smart Clinic’s longitudinal care capabilities to help families manage conditions that need more than episodic, acute care visits.

Study: TytoCare Home Smart Clinic Reduces Total Cost of Care by 7% for Health Plan Members

Retrieved on: 
Wednesday, July 12, 2023
Stanford University, Wheeze, Tyto, Trust, Journal, Patient, Journal of Health Economics, Diagnosis, FDA, Medical device, Nursing, Clalit Health Services, Tel Aviv University

The researchers found that the Home Smart Clinic led to a 12% increase in primary care utilization, 24.1% reduction in emergency room utilization, and an 11.3% reduction in urgent care utilization.

Key Points: 
  • The researchers found that the Home Smart Clinic led to a 12% increase in primary care utilization, 24.1% reduction in emergency room utilization, and an 11.3% reduction in urgent care utilization.
  • By directing patients to the right care to meet their needs, TytoCare utilization led to a 7% reduction in cost of care across all age groups, and a 9% reduction among adults.
  • The TytoCare Home Smart Clinic is the only all-in-one device on the market that can replicate the doctor’s office in the home.
  • Recently, TytoCare announced FDA approval for its AI-backed Tyto Insights™ for Wheeze Detection feature, enabling accurate remote diagnosis of wheezing via the Home Smart Clinic.

Biosimilar Therapeutic Peptides Global Market Report 2022: Featuring Eli Lilly, Sanofi, Amgen, Pfizer, Merck & More - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 30, 2022
Biotechnology, General Health, Pharmaceutical, Health, Growth, Dermatology, WHO, Degenerative disease, Peptide, Food and Drug Administration, Organization, Food, Conditional sentence, Biosimilar, Drug, Medicines and Healthcare products Regulatory Agency, Patient, Route of administration, Ageing, FDA, World Health Organization, Journal, Cancer, Administration, MHRA, Research, Tufts Center for the Study of Drug Development, Application, Food and Drug Administration Safety and Innovation Act, Medication, Infection, Journal of Health Economics, Drug development, Fine chemical, Pharmaceutical industry

The "Biosimilar Therapeutic Peptides Global Market Report 2022: By Route, By Application, By Type" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biosimilar Therapeutic Peptides Global Market Report 2022: By Route, By Application, By Type" report has been added to ResearchAndMarkets.com's offering.
  • The increasing aging population is projected to surge the patients with chronic diseases contributing to the biosimilar therapeutic peptides' market growth.
  • Therefore, long and costly drug approvals of new drug candidates are anticipated to hinder the growth of biosimilar therapeutic peptides market.
  • During the forecast period, biosimilar therapeutic peptides market is expected to witness a growth in research collaborations as well as research funding approvals.